bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

ZEUS - ziltivekimab Rx for atherosclerosis

Study location BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2
Principal Investigator Dr. Tom Elliott; **Co-Principal Investigator** Dr. David Lee
Study coordinator & primary contact Alireza Moshiri P: 604-628-7253 x 7013: amoshiri@bcdiabetes.ca
Summary: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Hypothesis: Inflammation is an additional important risk factor to address in patients with established atherosclerotic cardiovascular disease (ASCVD), especially those with chronic kidney disease (CKD). Ziltivekimab once-monthly injection shots reduces inflammation as measured by high-sensitivity C-reactive protein (hs-CRP), and thereby has the potential to reduce cardiovascular risk.
Eligible Participants include:

- Male or female aged > 18
- eGFR 15-60
- Serum hsCRP >/= 2 mg/L
- Evidence of ASCVD within 5 yrs (documented MI, coronary or carotid revascularization, stroke, > 50% stenosis in a major epicardial coronary artery or carotid artery documented by catheterization, angiography or doppler ultrasound, PAD with ABI </= 90 or > 50 % stenosis of a peripheral artery, lower extremity amputation due to atherosclerotic disease

Treatment course and duration:
The study is designed as a randomized, parallel-group, double-blind, placebo-controlled, multi-center, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomized 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.
Study goes for 3 years
Odds of receiving placebo 50%
Study documents:
pre-screen informed consent
post-screen informed consent
Protocol
Short URL = https://bit.ly/3H6Xwcs